Department of Thoracic Surgery, Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou, 515000, Guangdong Province, China.
World J Surg Oncol. 2022 May 4;20(1):143. doi: 10.1186/s12957-022-02607-0.
Esophageal adenosquamous carcinoma (EASC) is a rare disease. The biological behavior and treatment of this malignancy are not well studied.
Data from 56 patients with EASC who underwent esophagectomy were retrospectively analyzed and compared with 5028 patients with esophageal squamous cell carcinoma (ESCC). The impact of clinicopathological factors on the survival of patients with EASC was analyzed. The survival differences between patients with EASC and ESCC were also compared.
There were 43 males and 13 females with a mean age of 59.7 ± 1.3 years (range, 39-79 years). Only 1 of the 43 patients who received preoperative esophagoscopic biopsy was diagnosed with EASC. The median survival time for patients with EASC was 32.0 months, and the 1-, 3-, and 5-year overall survival rates were 78.3%, 46.1%, and 29.6%, respectively. Resection margin, pN category, and adjuvant chemotherapy were found to be independent predictors. After 1:1 propensity score matching, the 5-year overall survival rate of 29.6% for patients with EASC was similar to that of 42.5% for patients with ESCC (P = 0.179).
EASC is a rare disease and is easily misdiagnosed by esophagoscopic biopsy. The prognosis of EASC was similar to that of ESCC. Postoperative adjuvant chemotherapy may improve the survival of patients with EASC after esophagectomy.
食管腺鳞癌(EASC)是一种罕见的疾病。这种恶性肿瘤的生物学行为和治疗方法尚未得到充分研究。
回顾性分析了 56 例接受食管切除术的 EASC 患者的数据,并与 5028 例食管鳞癌(ESCC)患者进行了比较。分析了临床病理因素对 EASC 患者生存的影响,并比较了 EASC 患者和 ESCC 患者的生存差异。
患者中男性 43 例,女性 13 例,平均年龄 59.7±1.3 岁(范围 39-79 岁)。仅有 1 例接受术前食管内镜活检的患者被诊断为 EASC。EASC 患者的中位总生存时间为 32.0 个月,1、3 和 5 年总生存率分别为 78.3%、46.1%和 29.6%。切缘、pN 分期和辅助化疗是独立的预测因素。经过 1:1 倾向评分匹配后,EASC 患者 5 年总生存率为 29.6%,与 ESCC 患者的 42.5%相似(P=0.179)。
EASC 是一种罕见疾病,易被食管内镜活检误诊。EASC 的预后与 ESCC 相似。术后辅助化疗可能改善 EASC 患者食管切除术后的生存。